drugset

drugset / Trial / NCT07539415

A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers

NCT07539415 ↗

Phase 1 Recruiting 72 enrolled Daewoong Pharmaceutical Co. LTD.

RandomizedSequentialDouble-blindTreatment

Summary

Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults

Timeline

Start: 2026-05-06
Primary completion: 2026-10-27
Completion: 2026-11-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Semaglutide	Peptide	—	—

Indications